News Headlines

  1. Bavarian Nordic Receives U.S. FDA Approval Of Freeze-Dried Smallpox And Mpox Vaccine 3/31/2025

    Bavarian Nordic A/S today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS (Smallpox and Mpox Vaccine, Live, Non-replicating) for prevention of smallpox and mpox disease in adults 18 years of age and older.

  2. ABEC Unveils Breakthrough Single Use Bioreactor Technology For Cell Therapy Manufacturing 3/31/2025

    ABEC, a global leader in engineered solutions and services for biotech manufacturing, has introduced its Advanced Therapy Bioreactor (ATB) – a revolutionary platform poised to transform cell expansion for Advanced Therapy Medicinal Products (ATMPs).

  3. HAS Healthcare Advanced Synthesis SA Acquires Cerbios-Pharma SA To Create Leading International Group In The CDMO Sector, Backed By 65 Equity Partners 3/31/2025

    HAS Healthcare Advanced Synthesis SA (“HAS”), a leading international developer and producer of active pharmaceutical ingredients (APIs), high-potency active pharmaceutical ingredients (HPAPIs), and anticancer compounds, today announces the planned acquisition of Cerbios-Pharma SA (Cerbios), a globally recognised manufacturer of chemical and biological APIs, including in the fast-growing area of antibody drug conjugates (ADCs).

  4. Curium Completes The Acquisition Of Monrol As Part Of Its Plan To Significantly Expand Lutetium-177 Capacity And PET Footprint 3/28/2025

    Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczacıbaşı-Monrol Nuclear Products Co. (Monrol), a leading nuclear medicine player, which is headquartered in Istanbul, Turkey.

  5. PharmAla Contracts With Partner To Act As US Distributor 3/28/2025

    PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has contracted with a third party logistics company specializing in pharmaceutical products to act as its US clinical trial distribution partner.

  6. CDMO medac Group Celebrates The Launch Of The Next Production Line 3/28/2025

    medac Group, a trusted partner in contract development and manufacturing, proudly announces the successful commissioning of its latest investment: the third production line at oncomed, a state-of-the-art production site in the Czech Republic operated by medac.

  7. Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851 3/28/2025

    Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders.

  8. EnWave Signs Master Service Agreement And First Work Order With BioTechnique LLC 3/27/2025

    EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") announced today that it has signed a master service agreement (the “Agreement”) with BioTechnique, an American pharmaceutical contract manufacturing service provider.

  9. Thermo Fisher Scientific And Chan Zuckerberg Institute For Advanced Biological Imaging Collaborate To Further Understanding Of Human Cells 3/27/2025

    Thermo Fisher Scientific Inc., the world leader in serving science, has announced a Technology Alliance Agreement with the Chan Zuckerberg Institute for Advanced Biological Imaging (CZ Imaging Institute).

  10. Scinai Signs An Option Agreement To Acquire Rare Disease Company Pincell And Its Novel Antibody For Treating Severe Dermatological Conditions 3/27/2025

    Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and in providing CDMO services through its Scinai Bioservices unit, today announced that it entered into a binding option agreement for the acquisition of the Italian biotech company Pincell srl.